An FDA panel recommended the synthetic erythropoiesis-stimulating agent, or ESA, peginesatide as an alternative treatment for anemia in patients with chronic kidney disease undergoing dialysis. The drug, made by Affymax, works comparably to standard ESAs in increasing hemoglobin level and limiting blood transfusions in patients on dialysis, the panel said. The drug, if approved, will not be used in patients not on dialysis or patients with cancer.

Related Summaries